Navigation Links
Immune Deficiency Foundation Urges FDA To Exempt Immunoglobulin From Biosimilars Pathway
Date:5/17/2012

BALTIMORE, May 16, 2012 /PRNewswire/ -- In an effort to voice concern on biosimilars pathways for patients with primary immunodeficiency diseases (PIDD), the Immune Deficiency Foundation (IDF) offered oral testimony at last week's U.S. Food and Drug Administration (FDA) public hearing on draft guidance of biosimilars products. IDF urged the FDA to exempt immunoglobulin (Ig) therapies from the biosimilars pathways in order to protect the safety of patients with PIDD.

PIDD occurs in people born with an immune system that is either absent or hindered in its ability to function, causing an array of illnesses. Many of these patients require Ig therapy, a biologic medicine, for long-term management. Ig therapies are derived from human blood product, or plasma, and can differ in terms of processing and end composition.

"The FDA should restrict Ig therapies from the biosimilars pathways until the science advances significantly," said Marcia Boyle, president and founder, IDF. "Patients with primary immunodeficiency diseases depend on frequent antibody replacements with Ig therapy in order to fight infections."

The FDA recognizes each Ig brand as unique with no generic equivalent— Ig products are not clinically interchangeable. Current science cannot demonstrate that two products will provide the exact same clinical results for a large number of patients or that switching patients from one product to another will pose no additional risks.

Boyle's testimony urged the FDA to follow the example set by the European Medicines Agency and exempt Ig therapy from the biosimilars pathway, or to at the least require that biosimilars products undergo clinical trials to determine whether a proposed interchangeable therapy will offer patients the same clinical outcome. Additionally, Boyle requested that the FDA prohibit automatic substitution of a biosimilars with an original biologic.

"We believe the FDA's foremost responsibility is to ensure that biosimilars are manufactured and prescribed safely," said Boyle. "All medicines must be thoroughly tested and meet the highest safety standards set by the FDA."

About the Immune Deficiency Foundation

The Immune Deficiency Foundation is the national patient organization dedicated to improving the diagnosis, treatment and quality of life of persons with primary immunodeficiency diseases through advocacy, education, and research.  www.primaryimmune.org.


'/>"/>
SOURCE Immune Deficiency Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
2. Peptimmune Presentation at Upcoming World Congress on Treatment and Research in Multiple Sclerosis
3. EUPROBIO 2008 Presentation to Highlight Latest Immune Research
4. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
5. MedImmune Expands R&D Capacity with New Research Facility in Cambridge, U.K.
6. MedImmune Licenses Reverse Genetics Technology to Hungarys Omninvest for Use in Influenza Vaccine Development and Production
7. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
8. Peptimmune Presentations at Upcoming Events
9. Protein-printing technique gives snapshots of immune system defense
10. Visualizing asthma-causing immune cells at work
11. AutoImmune Inc. Reports 2008 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... Last week, ... for corporate executives and entrepreneurs, held The Future of San Diego Life Science event ... San Diego life science community attended the event with speakers Dr. Rich Heyman, former ...
(Date:5/23/2016)... ... May 23, 2016 , ... PrecisionAg® Media has released ... and Beyond. The paper outlines the key trends that are creating both opportunities ... witnessed a lot of highs and lows as the precision agriculture market has ...
(Date:5/23/2016)... May 23, 2016 - Leading CRO,s Use ... - Frontage Implement a Single Platform to Manage End-to-end Operations ... Within the Bioanalytical lab Frontage Laboratories, a full-service contract ... and China , has selected IDBS, ... In addition to serving as the global electronic lab notebook (ELN), ...
(Date:5/22/2016)... ... May 22, 2016 , ... Doctors in Rome say ... the asbestos cancer, malignant mesothelioma. Surviving Mesothelioma has just posted an article on the ... University of Rome’s Department of Clinical Sciences and Translational Medicine evaluated more than 150 ...
Breaking Biology Technology:
(Date:3/14/2016)... , March 14, 2016 NXTD ... growing mobile commerce market, announces the airing of a new ... starting the week of March 21 st .  The commercials ... including its popular Squawk on the Street show. --> ... on the growing mobile commerce market, announces the airing of ...
(Date:3/11/2016)... , March 11, 2016 ... new market research report "Image Recognition Market by Technology ... (Marketing and Advertising), by Deployment Type (On-Premises and Cloud), ... To 2022", published by MarketsandMarkets, the global market is ... to USD 29.98 Billion by 2020, at a CAGR ...
(Date:3/9/2016)... , March 9, 2016 This BCC ... future states of the RNA Sequencing (RNA Seq) market ... such as instruments, tools and reagents, data analysis, and ... various segments of the RNA-Sequencing market such as RNA-Sequencing ... Identify the main factors affecting each segment and forecast ...
Breaking Biology News(10 mins):